EHA2021 - WM and MZL - disease, diagnosis and the role of TLR/BCR pathway - BeiGene Medical Europe

EHA2021 - WM and MZL - disease, diagnosis and the role of TLR/BCR pathway

 VIDEO   00:13:56   06/2021

Rationale and Role of BTK Inhibition as a Treatment Strategy for Patients with Indolent B-Cell Lymphomas

Background and Insights on the Use of BTK Inhibitors Now and in Future in WM and MZL

WM and MZL - disease, diagnosis, role of TLR/BCR pathway

Shirley D'Sa

Rating

Rate this resource